Characterization of T‐DM1‐resistant breast cancer cells

Characterization of T‐DM1‐resistant breast cancer cells

Abstract The development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trast...

Full description

Bibliographic Details
Main Authors:	Juliette Sauveur, Louise Conilh, Sabine Beaumel, Kamel Chettab, Lars‐Petter Jordheim, Eva‐Laure Matera, Charles Dumontet
Format:	Article
Language:	English
Published:	Wiley 2020-08-01
Series:	Pharmacology Research & Perspectives
Subjects:	breast cancer HER2 resistance SLC transporters T‐DM1 tubulin
Online Access:	https://doi.org/10.1002/prp2.617

Similar Items

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
by: A. Geneste, et al.
Published: (2020-08-01)

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience
by: Nicolò Matteo Luca Battisti, et al.
Published: (2020-01-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Silvia D’Amico, et al.
Published: (2020-05-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report
by: Suman Kalyan Natarajan, et al.
Published: (2023-03-01)

Tumor Extrinsic Factors Mediate Primary T-DM1 Resistance in HER2-Positive Breast Cancer Cells
by: Yukinori Endo, et al.
Published: (2021-05-01)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
by: Mercedes Nadal-Serrano, et al.
Published: (2020-03-01)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
by: Matteo Allegretti, et al.
Published: (2021-11-01)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
by: Kamel Chettab, et al.
Published: (2023-05-01)

SLC35A2 expression is associated with HER2 expression in breast cancer
by: Yiran Wang, et al.
Published: (2024-04-01)

Tubulin Carboxypeptidase Activity Promotes Focal Gelatin Degradation in Breast Tumor Cells and Induces Apoptosis in Breast Epithelial Cells That Is Overcome by Oncogenic Signaling
by: Trevor J. Mathias, et al.
Published: (2022-03-01)

<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
by: Gaia Griguolo, et al.
Published: (2020-07-01)

Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
by: I V Kolyadina, et al.
Published: (2014-12-01)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
by: Luai S. Al Rabadi, et al.
Published: (2021-10-01)

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
by: Mark Barok, et al.
Published: (2018-05-01)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
by: Fabien Moinard-Butot, et al.
Published: (2022-06-01)

Personalized approach to HER2-positive advanced breast cancertherapy
by: M B Stenina
Published: (2014-09-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

Comparison of HbA1c Levels in Patients With TB-DM And TB-non DM
by: Nona Rahmaida Puetri, et al.
Published: (2019-12-01)

Reconstituting Microtubules: A Decades-Long Effort From Building Block Identification to the Generation of Recombinant α/β-Tubulin
by: Shih-Chieh Ti
Published: (2022-04-01)

Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
by: T Yu Semiglazova, et al.
Published: (2015-03-01)

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
by: G. Kallergi, et al.
Published: (2018-07-01)

Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease
by: Henhen Heryaman, et al.
Published: (2024-02-01)

Sequence Features of Mitochondrial Transporter Protein Families
by: Gergely Gyimesi, et al.
Published: (2020-11-01)

Slc2a6 regulates myoblast differentiation by targeting LDHB
by: Xuan Jiang, et al.
Published: (2022-07-01)

Reshaping the Binding Pocket of the Neurotransmitter:Solute Symporter (NSS) Family Transporter SLC6A14 (ATB<sup>0,+</sup>) Selectively Reduces Access for Cationic Amino Acids and Derivatives
by: Catriona M. H. Anderson, et al.
Published: (2022-10-01)

Sleep quality and associated factors among type 2 Dm patients and non-Dm individuals in Bahir Dar governmental hospitals: comparative cross-sectional study
by: Dagmawit Zewdu, et al.
Published: (2022-10-01)

Centriole triplet microtubules are required for stable centriole formation and inheritance in human cells
by: Jennifer T Wang, et al.
Published: (2017-09-01)

The contribution of genetic variants of SLC2A1 gene in T2DM and T2DM-nephropathy: association study and meta-analysis
by: I. Stefanidis, et al.
Published: (2018-10-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
by: E V Artamonova, et al.
Published: (2015-06-01)

The Complexities of Organ Crosstalk in Phosphate Homeostasis: Time to Put Phosphate Sensing Back in the Limelight
by: Lucile Figueres, et al.
Published: (2021-05-01)

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
by: Giuseppina Rosaria Rita Ricciardi, et al.
Published: (2018-01-01)

Heterologous (Over) Expression of Human SoLute Carrier (SLC) in Yeast: A Well-Recognized Tool for Human Transporter Function/Structure Studies
by: Lorena Pochini, et al.
Published: (2022-08-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Deciphering the Tubulin Language: Molecular Determinants and Readout Mechanisms of the Tubulin Code in Neurons
by: Riccardo Zocchi, et al.
Published: (2023-02-01)

HER2‐positive breast cancer brain metastasis: A new and exciting landscape
by: Alexandra S. Zimmer, et al.
Published: (2022-04-01)

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
by: A. Migeotte, et al.
Published: (2021-11-01)